CRESCENDO
Live / Registered — Registered (as of 06 Dec 2022)
What this means for you
Registered since 06 Dec 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79331946
- Registration number
- 6915016
- Mark type
- Design + words
- Filed
- 12 Aug 2021
- Published for opposition
- 20 Sept 2022
- Registered
- 06 Dec 2022
- Attorney of record
- Matthew L. Frisbee
Goods and services
- Class 001 — Chemicals: Chemicals for use in science and industry, namely, chemicals for laboratory research purposes; chemicals for use in science and industry, namely, chemicals for use in medical research; chemicals for use in science and industry, namely, chemicals for use in oncological research; antibodies and antibody fragments for scientific and laboratory use in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for scientific and laboratory use; antibodies and antibody fragments all being protein in raw material form for scientific research purposes; laboratory chemicals, namely, antibody reagents used in cell and tissue assays for scientific and laboratory use; biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in medical research; molecules primarily comprised of antibodies and antibody fragments in the nature of biochemicals, namely, monoclonal antibodies and antibody fragments for use in oncological research; antibodies and antibody fragments all being proteins for industrial use in the discovery, preclinical development, clinical development and manufacture of therapeutic products; chemicals used in industry and science
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; veterinary preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; therapeutic pharmaceutical preparations in the nature of antibodies and antibody fragments for medical and veterinary purposes; therapeutic preparations that use monoclonal antibodies, namely therapeutic pharmaceutical for treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibody fragments, being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases, for medical and veterinary diagnostics; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in the discovery, preclinical and clinical development of therapeutic products for medical and veterinary purposes; antibodies and antibody fragments being pharmaceutical preparations for the treatment of cancer, autoimmune diseases, inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, infections, organ transplant rejection, tissue transplant rejection, cardiovascular diseases, neurological disorders, degenerative disorders, metabolic disorders, dermatological diseases for use in oncology and therapeutic treatments in relation thereto; pharmaceutical preparations for use in oncology
- Class 031 — Natural agricultural products: Live animals; live mice
- Class 040 — Treatment of materials: Custom manufacture of chemicals, biologicals, antibodies and antibody fragments; services for the custom manufacture of therapies using antibodies and antibody fragments; custom manufacture of antibody and antibody fragments, for others, for use in medical therapies, including in relation to oncology; consultancy, advice and information relating to all of the aforesaid services
- Class 042 — Scientific and technological services: Scientific and technological services, namely, research and design in the field of chemicals, biologicals, antibodies and antibody fragments; scientific laboratory services relating to antibodies and antibody fragments; scientific and technological services, namely, provision of antibodies and antibody fragments for medical and veterinary research and development in the field of chemicals, biologicals, antibodies and antibody fragments; scientific services, namely, discovery, preclinical and clinical development of therapeutic products; scientific research for others in the field of drug discovery, preclinical and clinical development of therapeutic and diagnostic products; oncological research; engineering of antibodies and antibody fragments; research into antibodies, antibody fragments for others; research into the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments for others; consultancy, advice and information relating to all of the aforesaid services
- Class 045 — Legal and security services: Licensing of intellectual property, namely, licensing of research and development; licensing of intellectual property, namely, licensing of medical therapeutic research; licensing of intellectual property, namely, licensing of research relating to antibodies and antibody fragments; licensing of intellectual property, namely, licensing of research in relation to the formation, manufacture, medical usage and manipulation of antibodies and antibody fragments; consultancy, advice and information relating to all of the aforesaid services
Owner
Prosecution history
- 17 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 17 Jun 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 17 Jun 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 03 Jun 2025 — LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 08 Nov 2024 — RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
- 27 Oct 2023 — LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
- 19 Aug 2023 — RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
- 19 Apr 2023 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 29 Mar 2023 — FINAL DISPOSITION NOTICE SENT TO IB
- 28 Mar 2023 — FINAL DISPOSITION PROCESSED
- 06 Mar 2023 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 06 Dec 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 06 Dec 2022 — REGISTERED-PRINCIPAL REGISTER
- 27 Sept 2022 — NOTIFICATION PROCESSED BY IB
- 20 Sept 2022 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED